An update from BioCardia (BCDA) is now available.
BioCardia, Inc. has announced a significant development in its Phase 3 CardiAMP Heart Failure II Trial, with FDA approval for a protocol amendment. This change enables previously ineligible ischemic heart failure patients to receive additional cell therapy doses, tailored by the CardiAMP Cell Population Analysis, to meet a specific minimum treatment threshold. This advancement could potentially enhance the treatment options available for heart failure patients.
For an in-depth examination of BCDA stock, go to TipRanks’ Stock Analysis page.
